DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quart ...

Core Viewpoint - DaVita Inc. is expected to report third-quarter 2024 results on October 29, with revenue estimates at $3.22 billion, reflecting a 3.2% year-over-year increase, while EPS is projected at $2.76, indicating a 3.2% decline from the previous year [1] Financial Performance - In the last reported quarter, DaVita's EPS was $2.59, exceeding the Zacks Consensus Estimate by 4.9%, and the company has consistently outperformed earnings estimates over the past four quarters with an average earnings surprise of 24.2% [1] - Earnings estimates for DaVita's 2024 earnings have remained flat at $9.99 over the past 60 days [2] Revenue Drivers - Continued strength in revenue per treatment (RPT) has been a key contributor to DaVita's performance, supported by improvements in collection capabilities and targeted investments in technology [3][4] - Health plan negotiations have resulted in modestly higher rate increases due to inflation, which is expected to positively impact quarterly revenues [4] - Management anticipates stronger results from the Integrated Kidney Care business in the second half of the year, driven by timing of revenue recognition [4] International Expansion - DaVita has expanded its international operations in Brazil and Colombia, with acquisitions in Ecuador and Chile already closed, likely contributing additional revenues in the third quarter [4][10] Stock Performance - Year-to-date, DaVita's shares have gained 52.2%, outperforming the Medical - Outpatient and Home Healthcare sector's 16.8% rise, as well as the Zacks Medical sector's increase of 4.6% and the S&P 500's rise of 21.9% [6] - DaVita's forward 12-month price-to-earnings (P/E) ratio is 14.5X, which is a discount compared to the industry average of 21.2X and other industry players [7] Long-Term Outlook - DaVita is expected to maintain strong performance in 2024 due to investments in technology aimed at improving automation and claims processing [9] - The company is optimistic about its innovation track record and cost structure discipline, which are expected to enhance RPT growth [9] Investment Considerations - DaVita's core business strength, earnings potential, and global opportunities suggest favorable growth prospects, making it a consideration for existing investors [11] - The current valuation indicates potential for superior performance compared to industry peers, but the stock is still valued lower than the broader market, suggesting room for growth [11]

Core Insights - DaVita Clinical Research (DCR) is presenting five innovative research projects at the American Society of Nephrology's Kidney Week, focusing on improving racial equity in transplantation and clinical quality measures [1] - The research findings aim to enhance upstream chronic kidney disease (CKD) care management, prevent kidney failure, and promote health equity [1] Research Highlights - Nephrologist visits are associated with lower rates of hospitalization, mortality, and end-stage kidney disease (ESKD) transition in chronic kidney disease (CKD) patients [1] - Racial disparities in the transplant process have been identified among Hispanic patients on dialysis [1] - Heavy precipitation is linked to increased absenteeism in in-center dialysis treatment [1] - Early clinical indicators of ESKD transition or renal recovery have been studied in acute kidney injury (AKI) dialysis patients [1] - The study examines the relationship between systolic blood pressure thresholds and clinical outcomes in CKD stage 4/5 patients [1] Company Overview - DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally, serving approximately 265,100 patients at 3,124 outpatient dialysis centers as of June 30, 2024 [4] - DaVita has been a leader in clinical quality and innovation for over 20 years, working to reduce hospitalizations and improve mortality rates while promoting equitable care standards [4] - DCR assists pharmaceutical and medical device companies in designing and completing clinical trials through its renal research site network [3]

In the latest market close, DaVita HealthCare (DVA) reached $163.16, with a +1% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.05%. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.18%.The kidney dialysis provider's shares have seen a decrease of 0.02% over the last month, surpassing the Medical sector's loss of 4.16% and falling behind the S&P 500's gain of 2.76%.Investors will be eagerly watching for the perfo ...

Nephrologists drive transformative outcomes through government's coordinated care program serving high-need patientsDENVER, Oct. 22, 2024 /PRNewswire/ -- DaVita today announced performance year one clinical outcomes achieved in partnership with nearly 1,300 nephrologists across the U.S. through value-based care arrangements designed to enhance the lives of Medicare patients with kidney disease. As the broader health care community continues to explore value-based care arrangements to improve health outcomes ...

DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. Jess HergenreterJess Hergenreter "Our incre ...

DaVita HealthCare (DVA) ended the recent trading session at $164.82, demonstrating a +0.15% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 0.47%. At the same time, the Dow added 0.79%, and the tech-heavy Nasdaq gained 0.28%. Shares of the kidney dialysis provider witnessed a gain of 0.21% over the previous month, beating the performance of the Medical sector with its loss of 4.27% and underperforming the S&P 500's gain of 3.48%. Market participants will be closely ...

Shares of DaVita (DVA) have risen 115.5% in the past year, outperforming the Zacks Medical - Outpatient and Home Healthcare industry's growth of 37.8% and the broader Zacks Medical sector's return of 12.3%. The strong bull run in the DVA stock was primarily due to rising demand for its dialysis services, following the disruption of demand amid COVID-19. The upward trend is expected to persist through the remainder of 2024 and beyond, driven by increasing demand for dialysis services due to a growing number ...

Core Insights - DaVita Kidney Care has opened its dialysis centers in Florida to all patients in need of treatment following Hurricane Milton, ensuring uninterrupted access to life-sustaining care [1][3]. Company Response - DaVita activated its emergency response plan prior to Hurricane Milton, proactively treating thousands of patients in over 150 centers [3]. - The company has deployed essential resources, including water tankers, fuel tankers, generators, and additional supplies, to ensure centers can resume operations quickly in affected areas [3][4]. - DaVita's national emergency management team is coordinating care by directing patients to safe dialysis locations [4]. Patient Support - DaVita is reaching out to patients who may have missed treatments and providing them with necessary medical information for continuity of care [5]. - Patients can contact DaVita Guest Services for assistance in locating dialysis centers and scheduling treatments during the emergency [2]. Company Overview - As of June 30, 2024, DaVita served approximately 265,100 patients across 3,124 outpatient dialysis centers, with 2,672 located in the United States [7]. - DaVita has been a leader in clinical quality and innovation in kidney care for over 20 years, focusing on improving patient outcomes and reducing hospitalizations [7].

DENVER, Oct. 9, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Tuesday, October 29, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, October 29, 2024 Starting at 5:00 p.m. EDT Webcast can be accessed using this link Dial in number: ...